Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing innovative therapies for autoimmune diseases and cancer, has announced new preclinical findings regarding its investigational drug, CLN-978. This novel CD19xCD3 bispecific T cell engager has demonstrated significant potential in rapidly and effectively depleting B cells, both in laboratory settings and in living organisms, particularly in the context of various autoimmune diseases.
The company will present these findings at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, Illinois, from October 24 to 29. The poster presentation is scheduled for October 28, during the session from 10:30 a.m. to 12:30 p.m. CT, under Poster Session C, with the poster numbered 2293. Cullinan Therapeutics will also showcase its research at Booth 1074 in the Exhibit Hall.
CLN-978″s ability to induce substantial B cell depletion is particularly noteworthy, as B cells play a crucial role in the pathogenesis of numerous autoimmune disorders. By effectively targeting these cells, CLN-978 may offer a new therapeutic avenue for patients suffering from these challenging conditions. The preliminary data highlights the drug”s potential to provide a high-impact treatment option, which could be a significant advancement in managing autoimmune diseases.
As the field of immunotherapy continues to evolve, Cullinan”s research could open new doors for patients. The company”s commitment to advancing therapies that can profoundly impact patient care remains evident as it prepares to share these important findings with the scientific community.
